A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne

Exclusion Criteria

• •Female subjects who are pregnant, trying to become pregnant or breastfeeding.
• •Subjects who have any clinically relevant finding at their baseline physical examination or medical history such as severe systemic diseases, diseases of the facial skin, other than acne vulgaris.
• •Facial hair that may obscure the accurate assessment of acne grade.
• •History or presence of regional enteritis or inflammatory bowel disease (e.g., ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of antibiotic-associated colitis) or similar symptoms.
• •Use of topical antibiotics on the face and systemic antibiotics within the past 2 and 4 weeks, respectively.
• •Use of topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra-articular or intra-lesional (other than for facial acne lesions) steroids is acceptable.
• •Use of systemic retinoids within the past 6 months.
• •Concurrent use of drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the possibility of increased phototoxicity.
• •Concomitant use of neuromuscular blocking agents. Clindamycin has neuromuscular blocking activities, which may enhance the action of other neuromuscular blocking agents.
• •Use of topical anti-acne medications within the past 2 weeks.
• •Use of any investigational drugs or treatments during the study or within 4 weeks of the baseline visit.